Urocortin 3 contributes to paracrine inhibition of islet alpha cells in mice
Journal of Endocrinology · 2024
DOI: 10.1530/joe-24-0018 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Endocrinology, 2024. Verfasst von Glyn M Noguchi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurobiology, Physiology & Behavior, University of California Davis, Davis, California, USA. Hauptthemen laut MEDLINE: Urocortins, Glucagon-Secreting Cells, Paracrine Communication, Glucagon. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NIA NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
Pancreatic alpha cell activity and glucagon secretion lower as glucose levels increase. While part of the decrease is regulated by glucose itself, paracrine signaling by their neighboring beta and delta cells also plays an important role. Somatostatin from delta cells is an important local inhibitor of alpha cells at high glucose. Additionally, urocortin 3 (UCN3) is a hormone that is co-released from beta cells with insulin and acts locally to potentiate somatostatin secretion from delta cells. UCN3 thus inhibits insulin secretion via a negative feedback loop with delta cells, but its role with respect to alpha cells and glucagon secretion is not understood. We hypothesize that the somatostatin-driven glucagon inhibition at high glucose is regulated in part by UCN3 from beta cells. Here, we use a combination of live functional Ca 2+ and cAMP imaging as well as direct glucagon secretion measurement, all from alpha cells in intact mouse islets, to determine the contributions of UCN3 to alpha cell behavior. Exogenous UCN3 treatment decreased alpha cell Ca 2+ and cAMP levels and inhibited glucagon release. Blocking endogenous UCN3 signaling increased alpha cell Ca 2+ by 26.8 ± 7.6%, but this did not result in increased glucagon release at high glucose. Furthermore, constitutive deletion of Ucn3 did not increase Ca 2+ activity or glucagon secretion relative to controls. UCN3 is thus capable of inhibiting mouse alpha cells, but, given the subtle effects of endogenous UCN3 signaling on alpha cells, we propose that UCN3-driven somatostatin may serve to regulate local paracrine glucagon levels in the islet instead of inhibiting gross systemic glucagon release.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurobiology, Physiology & Behavior, University of California Davis, Davis, California, USA.
- Salk Institute for Biological Studies, La Jolla, California, USA.
- Department of Physiology & Membrane Biology, University of California Davis, Davis, California, USA.
ORCID-Profile: Mark O Huising
Förderung
- NIDDK NIH HHS
- NIA NIH HHS
- NIGMS NIH HHS
Zitieren
APA
Noguchi, G. M., Castillo, V. C., Donaldson, C. J., Flisher, M. R., Momen, A. T., Saghatelian, A., & Huising, M. O. (2024). Urocortin 3 contributes to paracrine inhibition of islet alpha cells in mice. Journal of Endocrinology. https://doi.org/10.1530/joe-24-0018
Vancouver
Noguchi GM, Castillo VC, Donaldson CJ, Flisher MR, Momen AT, Saghatelian A, et al. Urocortin 3 contributes to paracrine inhibition of islet alpha cells in mice. Journal of Endocrinology. 2024. doi:10.1530/joe-24-0018
BibTeX
@article{Noguchi2024,
author = {Noguchi, Glyn M and Castillo, Vincent C and Donaldson, Cynthia J and Flisher, Marcus R and Momen, Ariana T and Saghatelian, Alan and Huising, Mark O},
title = {Urocortin 3 contributes to paracrine inhibition of islet alpha cells in mice},
journal = {Journal of Endocrinology},
year = {2024},
doi = {10.1530/joe-24-0018}
}
EUVIMED